Happy with their divorce

Although much progress in drug discovery is due to cooperation between academia and industry, very close collaborations may result in toe-stomping, particularly when academic and industrial goals come to cross purposes. A good example is the tight binding of Human Genome Sciences Inc. with The Institute for Genomic Research (TIGR) under a 10-year agreement that came to an end last week.

HGSI Chairman and CEO William Haseltine acknowledged the value of the company's five-year association with TIGR. The

Read the full 776 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE